REXULTI is available as 2 mg tablets as well as other dosage strengths.
Please see IMPORTANT SAFETY INFORMATION by visiting https://tinyurl.com/26tdmdx4.
Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING by visiting tinyurl.com/yc6hwy2v.
This page is not intended for the reporting of side effects associated with the use of REXULTI.
To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).
This content is intended for U.S. HCPs.
© 2023 Otsuka America Pharmaceutical, Inc. All rights reserved. April 2023 11US23EBP0103
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.rexultihcp.com/
Rexulti® (Brexpiprazole) Hcp Questions
Rexulti® (Brexpiprazole) Hcp's website is https://www.rexultihcp.com/
Rexulti® (Brexpiprazole) Hcp's LinkedIn profile is https://www.linkedin.com/company/rexulti-hcp
Rexulti® (Brexpiprazole) Hcp's industry is
Pharmaceutical Manufacturing
Rexulti® (Brexpiprazole) Hcp's top competitors are
Tagrisso® (Osimertinib) Hcp,
Opdivo® (Nivolumab) Us Hcp,
Abbvie,
Zerbaxa® (Ceftolozane And Tazobactam) Hcp,
Benlysta (Belimumab),
Entyvio (Vedolizumab),
Keytruda® (Pembrolizumab) Hcp,
Otsuka Pharmaceutical Companies (U.s.),
Lundbeck,
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp.
Rexulti® (Brexpiprazole) Hcp's categories are Pharmaceutical Manufacturing
